Safety in these pediatric populations was consistent with the known safety profile across approved adult and pediatric indications1,2
States were also strongly advised to strictly monitor epidemiological profile of admitted COVID patients
This facility will produce higher efficacy products that enjoy greater acceptance and enhanced profit marginsg
73% have cited fears like losing eyesight, painful procedure or long recovery period when it comes to cataract surgeries
The FDA informed Astellas that it did not have sufficient information to assess the risks to subjects
Both vaccine candidates demonstrated a favorable safety and tolerability profile similar to the Pfizer-BioNTech COVID-19 Vaccine
Dr. Rizo brings extensive industry leadership experience to Vividion, having held multiple senior executive roles during her career at both biotechnology and large pharmaceutical companies.
The Minister directed officials to continue to focus on surveillance and on Whole Genome Sequencing to scan for any possible mutation and also directed for monitoring hospitalizations due to COVID-19 and SARI/ILI cases
An interim analysis of this data shows no significant safety issues and a 91% seroconversion rate at Day 56.
Intended for potential treatment of ER+/HER2- advanced or metastatic breast cancer patients
Subscribe To Our Newsletter & Stay Updated
